Drug Trial Radar · NCT01194414
A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Participants With Moderate to Severe Active Rheumatoid Arthritis
Last checked: Nov 20, 2026Latest source record: Jun 20, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,262
Actual
Start
Sep 2010
Primary completion
Jan 2012
Study completion Aug 2013
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Sep 3, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized, double-blind, parallel group study compares the efficacy and safety of subcutaneous (sc) versus intravenous (iv) administration of tocilizumab in participants with moderate to severe active rheumatoid arthritis. Participants were randomized to receive either tocilizumab 162 mg sc weekly plus iv placebo every 4 weeks, or tocilizumab 8 mg/kg iv every 4 weeks plus sc placebo weekly during the double-blind period from baseline to Week 24. The double-blind period was followed by a 72-week open-label treatment with some switching of sc and iv administration. No placebo was administered in the open-label phase. Participants continued on their stable dose of disease-modifying antirheumatic drugs (DMARDs) throughout the study. Anticipated time on study treatment was 2 years.
Conditions
- Rheumatoid Arthritis
Interventions
tocilizumab SCDrug
Tocilizumab supplied in a single-use pre-filled syringe, with a needle safety device, delivering 162 mg/0.9 mL solution for subcutaneous injection once a week.
tocilizumab IVDrug
Tocilizumab supplied in vials as a sterile solution for 8 mg/kg intravenous infusion every 4 weeks.
placebo to tocilizumab SCDrug
Placebo tocilizumab supplied as a single-use pre-filled syringe with a needle safety device, delivering 0.9 mL sodium chloride for subcutaneous injection once a week for 24 weeks in the double-blind period.
placebo to tocilizumab IVDrug
Placebo to tocilizumab supplied as a solution in 10 mL vials containing polysorbate 80 and sucrose in water for infusion every 4 weeks for a total of 24 weeks in the double-blind period.
Disease-modifying antirheumatic drugs (DMARDs)Drug
stable dose as prescribed
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving an American College of Rheumatology Criteria (ACR20) Response at Week 24Time frame: Baseline, 24 weeks
- Percentage of Participants With Adverse Events, Serious Adverse Events and Clinically Significant Laboratory AssessmentsTime frame: Baseline to up to 3 months after last dose of study drug (approximately up to 2 years)
Locations
216 sites in 26 countries. Site status is shown where the registry gives one.
Site not named
Huntsville, Alabama
Site not named
Tuscaloosa, Alabama
Site not named
Tucson, Arizona
Site not named
Tucson, Arizona
Site not named
Long Beach, California
Site not named
Los Angeles, California
Site not named
Upland, California
Site not named
Van Nuys, California
Site not named
Denver, Colorado
Site not named
Bridgeport, Connecticut
Site not named
Delray Beach, Florida
Site not named
Miami, Florida
Site not named
Ocala, Florida
Site not named
Orlando, Florida
Site not named
Palm Harbor, Florida
Site not named
Pinellas Park, Florida
Site not named
South Miami, Florida
Site not named
Tampa, Florida
Site not named
Coeur d'Alene, Idaho
Site not named
Morton Grove, Illinois
Site not named
Wichita, Kansas
Site not named
Monroe, Louisiana
Site not named
Petoskey, Michigan
Site not named
Saint Claire Shores, Michigan
Site not named
Eagan, Minnesota
Site not named
Florissant, Missouri
Site not named
St Louis, Missouri
Site not named
St Louis, Missouri
Site not named
Lebanon, New Hampshire
Site not named
Clifton, New Jersey
Site not named
Manalapan, New Jersey
Site not named
Voorhees Township, New Jersey
Site not named
Albuquerque, New Mexico
Site not named
Albany, New York
Site not named
Binghamton, New York
Site not named
Orchard Park, New York
Site not named
Asheville, North Carolina
Site not named
Raleigh, North Carolina
Site not named
Wilmington, North Carolina
Site not named
Cincinnati, Ohio
Showing 40 of 216 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.